Pernix Therapeutics Holdings Inc
Pernix Therapeutics — Investor Presentation (January 2011)
25 slides from Pernix Therapeutics's investor presentation, Jan 20, 2011

Slide 1: Investor Presentation January 2011
Investor Presentation January 2011

Slide 2: Safe Harbor Statement
The following presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward looking statements, whi

Slide 3: Pernix Today
Pernix Today Integrated Specialty Pharmaceutical Business Gross sales of $38.3 million in 2009, three-year CAGR of 41.5%; Profitable and generating cash flow Strong IP-Driven Operating Model Focus on branded pediatric products with high gross margins / low cap ex requirements; 23 trademark interests

Slide 4: Corporate Structure
Corporate Structure Pernix Therapeutics, LLC (Branded Pharmaceutical Products) Macoven Pharmaceuticals, LLC (Generic business) Wholly-owned subsidiary Gaine, Inc. (Intellectual Property Assets) Wholly-owned subsidiary Pernix Therapeutics Holdings, Inc. (Corporate)

Slide 5: Recent Milestones
■ Received FDA Approval for Human Head Lice Treatment in January 2011 o Product available in the first half of 2011 ■ Formed Joint Venture with UK Development Company in December 2010 o $1.5 million investment to fund late-stage development of theobromine-based treatment for persistent cough ■ Acqui

Slide 6: Strategic Plan
Strategic Plan Grow sales of Cedax and other existing products Identify new collaborations; Accretive acquisitions Develop new products; Expand into new markets beyond pediatrics Near-Term Medium-Term Long-Term Utilize sales force of 55 representatives in pediatrics Consider product expansion by acq

Slide 7: Current Product Portfolio
Products Active Categories Aldex Family Cold/Cough BC1036** Antitussive Brovex Family Cold/Cough Cedax Antibiotic Natroba Head Lice Pediatex Family Cold/Cough QuinZyme* Cardiovascular ReZyst IM Gastro-Probiotic Z-Cof Family Cold/Cough Zema-Pak Corticosteroid Therapy Current Product Portfolio * Partn

Slide 8: Current/Future Sales Force
Current/Future Sales Force 2009 Total Employees: ~80 2010 Sales Representatives: 55 2010 Q4 Sales Force Additions: 10-12 (Goal) 2011 and beyond - increase reach to mid-decile prescribers with increased frequency

Slide 9: Sales Force Efficiency
Sales Force Efficiency • Pernix sales force averaged almost 560 RX’s per rep for the Pediatex TD Product in the 4 th month of the launch Launch of Pediatex Launch of Brovex • Pernix acquired the Brovex product line for $450,000 in June 2009 • Following the product launch in August 2009, the Pernix s

Slide 10: Cedax
o Only competing third generation cephalosporin product generated nearly $100 million of sales at retail in 2009 o Opportunity to expand into oral solid market through co-promotion efforts ■ Indicated Treatment for Middle Ear Infections o Antibiotics are promotion sensitive and highly prescribed in

Slide 11: Natroba
■ Pernix expects to receive payments between 35%-42% of net sales proceeds ■ Received FDA Approval for Use in Patients Ages 4 and Up in January o According to two phase III studies, the product was shown as significantly more effective in eliminating head lice than permethrin 1% (Nix, AAP recommende

Slide 12: Growth Strategy
Growth Strategy

Slide 13: Macoven Pharmaceuticals
§ Profitable Generics Division o Provides opportunity for alternative revenue stream, authorized generics o Transaction funded with initial draw on line of credit § Launched 11 Generic Pharmaceutics in 2010 o Includes five authorized generic equivalents of Pernix branded products, as of September 30

Slide 14: Development Pipeline
§ Identify Partners to Efficiently and Cost Effectively Bring New Products to Market § Rights to 8 Product Candidates as of August 16, 2010 o Four antitussive product candidates o Two product candidates to treat symptoms associated with dermatitis o One product candidate in our Z-COF product line o

Slide 15: Natural Cough Suppressant
§ Joint Venture Formed with SEEK (UK) to Develop Codeine-Free Cough Suppressant (BC1036) o Pernix believes this antitussive candidate has potential to address the need for a safer and more effective, non-opioid treatment for persistent cough o Pernix contributed $1.5 million and its theobromine IP (

Slide 16: Management Team
Title Cooper Collins President and Chief Executive Officer Tracy Clifford Chief Financial Officer, Secretary and Treasurer Robert Cline Vice President, Operations and Supply Chain Management Mike Venters Vice President, Corporate Development Beth DeVille Vice President, Sales and Marketing Managemen

Slide 17: Market Opportunity
Market Opportunity

Slide 18: Cough and Cold Market
§ Cold/Cough Sector-Annual Sales in Excess of $2 billion 1 § Over 35.9 Million People have Seasonal Allergic Rhinitis, Accounting for $4.5 Billion Spent on Direct Care 2 § Allergic Disease Affects More Than 20% of the Population and is the 3rd Leading Chronic Disease Among Children Under 18 Years of

Slide 19: Antibiotics and Lice Market
§ Over 5 Million Cases of Middle Ear Infections Occur Annually in Children, Which Resulted in 10 Million Antibiotic Prescriptions per Year 1 § Middle Ear Infections are the Most Common Illnesses Experienced by Babies and Young Children o Number one cause of consultations with physicians § The U.S. C

Slide 20: Financials
Financials

Slide 21: Profitable Growth
Historical sales growth driven by increasing demand for Brovex, Pediatex, Aldex and Z-Cof products Profitable Growth Consistent growth in earnings resulting from focus on high margin product sales and lean operating structure

Slide 22: Condensed Income Statement
($, in millions except per share data) Three Months Ended September 30 Nine Months Ended September 30 2010 2009 2010 2009 Net Sales 7.8 5.8 21.0 19.6 Gross Profit 6.3 4.1 17.7 15.4 Selling, General & Administrative Expense 3.3 2.3 9.4 7.4 Income from Operations 3.2 1.1 7.9 6.6 Net Income 2.4 1.1 7.8

Slide 23: Financial Position
As of September 30, 2010 ($, in millions) Cash and Cash Equivalents 8.2 Working Capital 5.6 Total Assets 36.6 Total Debt 2.2 For the Nine Months Ended September 30, 2010 ($, in millions) Cash Flow from Operations 2.1 CapEx 0.1 Free Cash Flow 2.0 Financial Position Definition : We define free cash fl

Slide 24: Investment Considerations
Investment Considerations Integrated Specialty Pharmaceutical Business Gross sales of $38.3 million in 2009, three-year CAGR of 41.5%; Profitable and generating cash flow Strong IP-Driven Operating Model Focus on branded pediatric products with high gross margins / low cap ex requirements; 23 tradem

Slide 25: Pernix Therapeutics Holdings, Inc. Thank You
Pernix Therapeutics Holdings, Inc. NYSE Amex: PTX Cooper Collins, President & CEO 33219 Forest West Drive Magnolia, TX 77354 www.pernixtx.com Thank You
Source: SEC EDGAR · 8-K filed Jan 20, 2011
More decks from Pernix Therapeutics Holdings Inc
Merger or Acquisition (February 2019)56 slides · Feb 19, 2019
Corporate Update (July 2017)27 slides · Jul 20, 2017
Corporate Update (July 2017)12 slides · Jul 20, 2017
PTX DISCUSSION MATERIALS DATED DECEMBER 22, 201636 slides · Dec 27, 2016
Investor Presentation (September 2015)27 slides · Sep 29, 2015
FY2011 Earnings Presentation31 slides · Mar 7, 2012